Experts highlighted research showing that even mild COVID can result in cognitive impairment including brain fog and IQ decline, the FDA approved Pfizer's RSV vaccine for adults aged 18 to 59, E coli outbreak linked to McDonald's Quarter Pounders, and more.
Without a specific tailored Long COVID therapy, individualized treatment based on patient phenotypes, along with extensive evaluations, is essential for effective symptom management.
Links to consumed hamburgers have resulted in 75 infections and one fatality, prompting an investigation of the slivered onions used on these beef patties.
Christine Slover, PharmD discussed cefiderocol's effectiveness against challenging infections, including those caused by multi-drug resistant bacteria.
David Richards emphasized the therapy’s potential to enhance antibiotic effectiveness by targeting bacterial biofilms, a significant challenge in treatment.
This new indication for the bivalent respiratory syncytial virus prefusion F vaccine (Abrysvo) makes it the broadest currently available.
Important vaccine updates, including a second COVID-19 vaccine dose for adults 65 and older and immunocompromised individuals, a pneumococcal vaccine for adults aged 50 and older, and more.
Nigel McCracken, PhD, presents a diagnostic test to identify early T cell dysfunction in syndromes like Long COVID and ME/CFS, aiming to improve treatment strategies before symptoms escalate.
Timothy Ritter, MD, provides his insights on using the live biotherapeutic product and what both patients and clinicians can expect in terms of safety and efficacy.
Anushua Sinha, MD, discussed the findings, highlighting a 60.4% reduction in medically attended lower respiratory infections and significant decreases in RSV-related hospitalizations.
Debika Bhattacharya, MD MSc, and Su H. Wang, MD, MPH, FACP, provide important insights on the latest in hepatitis B (HBV) clinical care.
The STOP-CDI intervention presented by Matthew J.Ziegler, MD MSCE revealed using prophylactic enteral vancomycin, significantly reduced hospital-onset C difficile infections among immunocompromised patients.
John McLaughlin, PhD, examines high-risk individuals with prior SARS-CoV-2 immunity and presents that Paxlovid reduces the risk of hospitalization, death, and severe symptoms, highlighting its ongoing value for high-risk patients in a post-peak pandemic landscape.
Invivyd’s Chief Scientific Officer Robert Allen, PhD, discusses the company’s pemivibart (Pemgarda) including its administration, how it can be used in concert with vaccines, and how it protects against newer variants.
Elizabeth Hastie, MD discussed the LATITUDE trial results, highlighting the need for wider access to this treatment, especially for those not virally suppressed, and could help shape future healthcare guidelines.
The individuals are agricultural workers in Washington state who were in close proximity to and working with infected poultry at an egg farm.
Study results show that the vaccine elicits a comparable immune response in high-risk adults aged 18-59 with chronic medical conditions, suggesting potential for broader vaccination efforts.
With the approval of newer products, clinicians have tools to prevent the respiratory virus in the most vulnerable population. Helen Chu, MD, MPH, offers some insights on their efficacy and the nuances of the delivery of the 2 immunizations.
The late-breaking ID Week session reported on the once-weekly oral regimen being studied for use in people with HIV who are virologically suppressed.
Evelyn Wu, MD, reveals a rise in tick-borne diseases in New Jersey over the past two decades and correlations with the influence of warming climate conditions.
Cornelius Clancy, MD, highlights the real-world outcomes of cefiderocol treatment for serious gram-negative bacterial infections, reporting a clinical success rate of 75% along with encouraging safety data.
At ID Week 2024, in a late-breaking presentation, investigators are reporting it is safe to cut the antibiotic regimen in half without endangering patients for these infections.
In our latest roundtable series, experts highlighted research showing that even mild COVID can result in cognitive impairment including brain fog and IQ decline.
Peggy Lillis Foundation CEO Christian Lillis believes patients need a seat at the table so he is advocating for past patients to become ambassadors to be a voice to help shape treatment and also continue to raise awareness about the infection.
Sean N Tucker, PhD, highlighted that VXA-GI.1-NN demonstrated safety and efficacy in reducing norovirus infections, marking a potential treatment in prevention for a diverse range of demographics.
At ID Week 2024, ViiV Healthcare reports its long-acting PrEP, cabotegravir (Apretude), is more than 99% effective.
Catherine Chappell, MD, MSc, presents what we know so far, highlighting the safety and effectiveness of direct-acting antivirals, the importance of shared decision-making, and the need for patient-provider discussions to ensure informed choices about care.
At ID Week 2024, an investigator, Amanda M. Casto, MD, PhD, discusses her work on the CASCADIA study, which examined infection rates in this setting, and how it challenged assumptions that there is likely a singular carrier bringing viruses into homes.
Nabin K. Shrestha, MD, MPH, evaluates the Cleveland Clinic's Outpatient Parenteral Antimicrobial Therapy (OPAT) program, revealing its effectiveness in managing infections while highlighting challenges in monitoring and the impact of infectious disease pharmacists on patient outcomes.
Karine G. Le Roch, PhD, discussed her research on a kalihinol analog that combats drug resistance in malaria, emphasizing the need for innovative treatments in the context of climate change and rising transmission rates.
